This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cuenca-Estrella, M.
Right arrow Articles by Rodriguez-Tudela, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuenca-Estrella, M.
Right arrow Articles by Rodriguez-Tudela, J. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2004, p. 3107-3111, Vol. 48, No. 8
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.8.3107-3111.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates

Manuel Cuenca-Estrella,* Alicia Gomez-Lopez, Emilia Mellado, Guillermo Garcia-Effron, and Juan L. Rodriguez-Tudela

Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadajonda (Madrid), Spain

Received 23 March 2004/ Returned for modification 2 April 2004/ Accepted 18 April 2004

The activities of ravuconazole and four other antifungal agents were tested against a collection of 1,796 clinical yeast isolates, including fluconazole-susceptible and -resistant strains. Ravuconazole was active against the majority of fluconazole-resistant isolates; but for 102 of 562 (18%) resistant isolates, mainly Candida tropicalis, Candida glabrata, and Cryptococcus neoformans, ravuconazole MICs were ≥1 µg/ml.

* Corresponding author. Mailing address: Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo Km. 2, 28220 Majadahonda (Madrid), Spain. Phone: 34-91-5097961. Fax: 34-91-5097966. E-mail: mcuenca-estrella{at}isciii.es.

Antimicrobial Agents and Chemotherapy, August 2004, p. 3107-3111, Vol. 48, No. 8
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.8.3107-3111.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., Perlin, D. S. (2009). Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-{beta}-D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint. Antimicrob. Agents Chemother. 53: 3690-3699 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Monzon, A., Rodriguez-Tudela, J. L. (2005). In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi. Antimicrob. Agents Chemother. 49: 5136-5138 [Abstract] [Full Text]  
  • Perkins, A., Gomez-Lopez, A., Mellado, E., Rodriguez-Tudela, J. L., Cuenca-Estrella, M. (2005). Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56: 1144-1147 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»